Celebration of Ipsen Canadian Headquarters Grand Opening in Mississauga, Ontario



From left to right: Lyndal Walker, Marc de Garidel, Hon. Dipika Damerla, Cynthia Schwalm, Marc Trouyet.

Ipsen will join Ontario’s growing biomedical cluster and deliver innovative specialty medicines based on its expertise and leadership in peptide and toxin research and drug development. The province’s strong research-based pharmaceutical and biopharmaceutical industries and the presence of leading hospitals with globally-recognized clinical research capabilities were key factors in Ipsen’s decision to establish its Canadian head office in the province.

Health and well-being are amongst the sectors of excellence of French companies. It is also one of the export fields that the French authorities are being promoting with determination. The creation of an IPSEN affiliate in Canada is the fruit of the encounter between a leading and innovative French company with a Canadian reality made up of excellence in the fields of clinical research and biotechnologies. And this reality is strongly represented here in the Greater Toronto Area. What we witness here today is the typical partnership and exchange between France and Ontario that we are actively pursuing, with the view to being up to the Province’s dynamic economy.


Marc Trouyet, Consul General of France in Toronto

Ipsen’s expansion to Canada will provide tangible benefits in support of the medical community and patients, as well as economic growth and job creation. Our mission is to develop and deliver innovative therapies to treat grievous illnesses and provide health care providers and patients with the right care, at the right place, at the right time.


Lyndal Walker, Country Manager, Ipsen Biopharmaceuticals Canada Inc.

We see significant opportunity in Canada and we are especially delighted to have access to Ontario’s incredibly skilled and diverse workforce in Canada’s largest life sciences cluster. Not only are we celebrating the opening of our new Canadian headquarters, but we’re also celebrating the Health Canada approval for Somatuline® Autogel® to treat Canadians living with enteropancreatic neuroendocrine tumours which gives health care professionals and these patients another weapon in the fight against the disease.


Marc de Garidel, Chairman and CEO of Ipsen


For further information, please visit www.ipsen.ca

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022